ABVC BioPharma, Inc.
ABVC
$2.41
-$0.12-4.74%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 796.00K | -- | -- | 13.60K | 389.30K |
| Total Other Revenue | -- | -- | -- | -11.60K | 9.30K |
| Total Revenue | 796.00K | -- | -- | 2.00K | 389.30K |
| Cost of Revenue | -- | -- | -- | 0.00 | 300.00 |
| Gross Profit | 796.00K | -- | -- | 2.00K | 389.00K |
| SG&A Expenses | 1.93M | 2.26M | 664.10K | 304.10K | 653.50K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -2.20K | -- | -- | 45.50K | 7.10K |
| Total Operating Expenses | 1.96M | 2.30M | 693.00K | 381.70K | 698.70K |
| Operating Income | -1.17M | -2.30M | -693.00K | -379.70K | -309.50K |
| Income Before Tax | -1.29M | -2.31M | -944.20K | 128.90K | -487.10K |
| Income Tax Expenses | 500.00 | 23.60K | -- | 0.00 | 400.00 |
| Earnings from Continuing Operations | -1.29M | -2.33M | -944.20K | 128.90K | -487.40K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 41.00K | 75.80K | 102.10K | 100.40K | 92.70K |
| Net Income | -1.25M | -2.26M | -842.10K | 229.30K | -394.80K |
| EBIT | -1.17M | -2.30M | -693.00K | -379.70K | -309.50K |
| EBITDA | -1.16M | -2.29M | -686.00K | -369.30K | -302.40K |
| EPS Basic | -0.05 | -0.13 | -0.06 | 0.02 | -0.03 |
| Normalized Basic EPS | -0.03 | -0.08 | -0.03 | 0.02 | -0.01 |
| EPS Diluted | -0.05 | -0.13 | -0.06 | 0.02 | -0.03 |
| Normalized Diluted EPS | -0.03 | -0.08 | -0.03 | 0.02 | -0.01 |
| Average Basic Shares Outstanding | 23.26M | 17.39M | 14.97M | 13.20M | 12.41M |
| Average Diluted Shares Outstanding | 23.26M | 17.39M | 14.97M | 13.20M | 12.41M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |